anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There is evidence that maternal milieu and changes in environmental factors during the prenatal period may exert a lasting impact on the brain health of the newborn, even in case of neonatal brain hypoxia-ischemia (HI). The present study aimed to investigate the effects of maternal environmental enrichment (EE) on HI-induced energetic and metabolic failure, along with subsequent neural cell responses in the early postnatal period. Male Wistar pups born to dams exposed to maternal EE or standard conditions (SC) were randomly divided into Sham-SC, HI-SC, Sham-EE, and HI-EE groups. Neonatal HI was induced on postnatal day (PND) 3. The Na+,K+-ATPase activity, mitochondrial function and neuroinflammatory related-proteins were assessed at 24 h and 48 h after HI. MicroPET-FDG scans were used to measure glucose uptake at three time points: 24 h post-HI, PND18, and PND24. Moreover, neuronal preservation and glial cell responses were evaluated at PND18. After HI, animals exposed to maternal EE showed an increase in Na+,K+-ATPase activity, preservation of mitochondrial potential/mass ratio, and a reduction in mitochondrial swelling. Glucose uptake was preserved in HI-EE animals from PND18 onwards. Maternal EE attenuated HI-induced cell degeneration, white matter injury, and reduced astrocyte immunofluorescence. Moreover, the HI-EE group exhibited elevated levels of IL-10 and a reduction in Iba-1 positive cells. Data suggested that the regulation of AKT/ERK1/2 signaling pathways could be involved in the effects of maternal EE. This study evidenced that antenatal environmental stimuli could promote bioenergetic and neural resilience in the offspring against early HI damage, supporting the translational value of pregnancy-focused environmental treatments.
Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved \[i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)\] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
Chronic Lymphocytic Leukemia

Of 336 patients with previously untreated CLL who received GAZYVA in combination with chlorambucil, 81% were 65 years and older, while 46% were 75 and older. Of the patients 75 years and older, 46% experienced serious adverse reactions and 7% experienced adverse reactions leading to death. Of the patients younger than 75, 33% experienced a serious adverse reaction and 2% an adverse reaction leading to death. No significant differences in efficacy were observed between younger and older patients [see Clinical Studies (14.1)].

Non-Hodgkin Lymphoma

Of 204 patients in GADOLIN with relapsed or refractory NHL treated with GAZYVA plus bendamustine, 44% were 65 and over, while 14% were 75 and over. In patients 65 and over, 55% of patients experienced serious adverse reactions and 28% experienced adverse reactions leading to treatment withdrawal while in patients under 65, 37% and 14% experienced serious adverse reactions and adverse reactions leading to treatment withdrawal, respectively. No clinically meaningful differences in efficacy were observed between these patients and younger patients in GADOLIN.

Of the 691 patients in GALLIUM treated with GAZYVA plus chemotherapy as first-line therapy, 33% were 65 and over, while 7% were 75 and over. Of patients 65 and over, 63% experienced serious adverse reactions and 26% experienced adverse reactions leading to treatment withdrawal, while in patients under 65, 43% experienced serious adverse reactions and 13% had an adverse reaction leading to treatment withdrawal. No clinically meaningful differences in efficacy were observed between these patients and younger patients in GALLIUM.
This study aims to analyze the correlation between Systemic Inflammatory Response Index (SIRI) and the severity of coronary artery stenosis in patients with coronary heart disease (CHD). It also aims to assess the predictive value of SIRI for the severity of coronary artery stenosis. A total of 2990 patients who underwent coronary angiography were included in this study. The Gensini score was used to estimate the severity of coronary vascular lesions. The predictive ability of SIRI for CHD was evaluated using receiver operating characteristic (ROC) curves. Binary multivariate logistic regression analysis was used to predict the likelihood of CHD based on the SIRI index. The results showed that people with higher SIRI were more likely to have CHD (P < 0.001). After controlling for other risk factors, the highest quartile had a significantly higher incidence of coronary artery disease compared to the lowest quartile (odds ratio [OR] 2.25, 95% confidence interval [CI] 1.73-3.92, P < 0.001). Furthermore, the Gensini score was significantly higher in the fourth quartile group (T4) compared to the first (T1) and second (T2) quartile groups (P < 0.001). Additionally, the SIRI was significantly higher in the group with severe coronary artery lesions compared to the mild and moderate groups (P < 0.001). The SIRI also showed a higher predictive ability for the extent of coronary lesions under the ROC curve compared to other commonly used markers, including platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-lymphocyte ratio (NLR) (P < 0.001). Therefore, SIRI positively correlates with coronary artery stenosis in CHD patients, serving as an effective early screening marker for assessing stenosis severity.
Chronic pruritus (CP) is frequent in general medicine and the most common complaint in general dermatology. The prevalence of CP is expected to rise in the future due to the ageing population. The clinical presentation, underlying aetiology and treatment strategy of CP are heterogeneous. Also, individual treatment aims and physical, psychic and economic burdens of patients might vary. Chronic prurigo (CPG) is the most severe disease in the chronic pruritus spectrum, being associated with long-standing scratch-induced skin lesions and a therapy refractory itch-scratch-cycle. It is thus important to raise disease awareness for CP and CPG in the general public and among decision-makers in the health system. Further, there is a need to support a rational clinical framework to optimize both diagnostics and therapeutics. Currently, there is still a shortcoming regarding approved therapies and understanding CP/CPG as severe medical conditions. Therefore, the EADV Task Force Pruritus decided to publish this white paper based on several consensus meetings. The group consented on the following goals: (a) ensure that CP is recognized as a serious condition, (b) increase public awareness and understanding of CP and CPG as chronic and burdensome diseases that can greatly affect a person's quality of life, (c) clarify that in most cases CP and CPG are non-communicable and not caused by a psychiatric disease, (d) improve the support and treatment given to patients with CP to help them manage their disease and (e) publicize existing therapies including current guidelines. We aim to point to necessary improvements in access and quality of care directed to decision-makers in health policy, among payers and administrations as well as in practical care.
Participants will participate in 2 preflight study sessions consisting of a VTC fit check and a baseline data collection without and with the VTC donned. Participants will also participate in 3 inflight study sessions: a VTC fit check on flight day 30 (FD30) and two separate data collection sessions on flight day 45 (FD45) and 45 days before landing (R-45). During the two in-flight data collection days, participants will be studied before and for up to 6 hours after donning the VTC.
All study participants. The ex vivo are performed at the screening visit and every two months+/- 1 and when an active case of tropical infection occurs.
Circular RNAs (circRNAs) have been found to be abnormally expressed in many cancers, including colorectal cancer (CRC). Circ_0053277 has been found to mediate CRC malignant processes and may be a key regulator for CRC progression. Therefore, its role and potential molecular mechanism in CRC process deserve further investigation. Quantitative real-time PCR was used to detect the expression levels of circ_0053277, microRNA-520 h (miR-520 h) and hexokinase 1 (HK1). Cell Counting Kit-8, 5-ethynyl-2'-deoxyuridine assay, flow cytometry, wound healing assay, transwell assay, and tube formation assay were used to detect CRC cell proliferation, apoptosis, migration, invasion, and angiogenesis. The protein levels of apoptosis-related markers and HK1 were detected by western blot. The relationship between circ_0053277 and miR-520 h or miR-520 h and HK1 in CRC cells was verified by dual-luciferase reporter assay, RNA immunoprecipitation assay and RNA pull-down assay. Cell glycolysis was assessed by detecting glucose uptake and lactate production. The effect of silenced circ_0053277 on CRC tumor growth was evaluated by xenograft model in vivo. Our study found that circ_0053277 expression was elevated in CRC tissues and cells. Moreover, circ_0053277 knockdown suppressed CRC cell proliferation, angiogenesis, migration and invasion, while promoting apoptosis. In terms of mechanism, circ_0053277 sponged miR-520 h, and HK1 was the target of miR-520 h. Meanwhile, miR-520 h inhibitor reversed the inhibitory effect of circ_0053277 silencing on CRC cell progression, and HK1 overexpression also overturned the suppressive effect of miR-520 h on CRC cell growth, angiogenesis and metastasis. Moreover, circ_0053277 knockdown inhibited the glycolysis of CRC cells by regulating miR-520 h/HK1 pathway. In addition, knockdown of circ_0053277 reduced CRC tumor growth in vivo. Circ_0053277 promoted CRC cell growth, angiogenesis, metastasis and glycolysis by miR-520 h/HK1 pathway, confirming that circ_0053277 might be a potential clinical target for CRC treatment.
Substance addiction (SA) is a risk factor of suicidal thoughts and behaviors (STB), although it is still unclear which SAs are reliably associated with increased risk for suicidal ideation, planning, and attempt. The current study aimed to meet this goal using data from the National Survey on Drug Use and Health (NSDUH) referring to years from 2008 to 2020. The information extracted included sociodemographic and contextual information, eleven SAs (e.g., nicotine, alcohol, marijuana, cocaine, pain relievers, heroin, inhalants, hallucinogens, sedatives, stimulants, and tranquillizers), and STB. The analysis revealed that SAs for alcohol, pain relievers, marijuana, and cocaine were stable and reliable predictors for STB (e.g., suicidal ideation, planning, and attempt), while cocaine was not a stable predictor for suicide attempt. The selected SAs model showed a greater predictive accuracy than only sociodemographic and contextual factors as well as not selected SAs. Moreover, selected SAs showed comparable predictive accuracy to the full model. Furthermore, SA to alcohol showed to be an extremely effective predictor of STB, having a comparable predictive accuracy to all the other ten SAs together. In conclusion, SAs to pain relievers, alcohol, marijuana, and cocaine can be considered as important risk factors for concurrent STB.
PURPOSE:To obtain a water-based preparation containing vitamin E in high concentration and useful as a medicine such as ophthalmic solution, by using vitamin E or its fatty acid ester at a concentration essentially higher than the solubility in water at normal temperature and emulsifying the compound or dissolving the compound by the aid of a dissolution assistant. CONSTITUTION:A water-based preparation containing homogeneously dissolved vitamin E in high concentration can be produced by adding a dissolution assistant (e.g. polysolvate 80, polyoxyethylene hardened castor oil, etc.) to a vitamin E compound (e.g. Dl-alpha-tocopherol, d-alpha-tocopherol acetate, etc.). As an alternative, a water-based preparation containing emulsified vitamin E in high concentration is obtained by emulsifying a vitamin E compound with an emulsifier such as soybean lecithin. The water-based preparation has sufficiently high concentration (1-30%) to exhibit remedying effects such as antioxidation activity, oxygen- retaining activity, etc., and is applicable as an ophthalmic solution, etc.
Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and obinutuzumab (BG). Participants received six 28-day cycles of BG+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
PURPOSE:To exactly and properly control stock without stopping on-line processing in a stock control system for medicines in a hospital or the like by preparing a stock remaining quantity as of the end of the last month and a present stock quantity on a master record, correcting the remaining stock quantity as of the last month with the actual stock quantity as of the end of the last month, and compensating the present stock quantity with the corrected stock quantity. CONSTITUTION:A remaining stock quantity as of the last month 11 and a present stock quantity 12 are prepared on a stock master record 1. This present stock quantity 12 is set to the same quantity as the remaining stock quantity as of the end of the last month as a initial value when a system is constructed. And, an on-line renewal (a) such as for stock, delivery, etc., from a terminal 2 is made only to the present stock quantity 12. And, the stock quantity at the end of the last month x 11 is amended (b) by stocktaking data obtained at the end of month. Next, x'-x is obtained as a compensation value for compensating the present stock quantity y 12, and the theoretical stock quantity y' at present can be obtained. By this constitution, the stock control without stopping on-line processing is made possible.
Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; \> 6 months: range of 5-10 ng/ml is recommended.
PURPOSE:To obtain a fibrous aggregate of micromolecules by dispersing an amphipatic substance contg. an amino acid residue represented by a specified general formula in distilled water and by carrying out ultrasonic treatment. CONSTITUTION:A fibrous aggregate of micromolecules made of a single kind of molecules and having amphipatic property comparable to that of natural lipid is produced by utilizing hydrogen bonding strength between amino acid residues and hydrophobic interaction between long chain alkyl groups. For example, a compd. represented by formula I [where X is halogen, (n) is an integer and R is 12-22C long chain alkyl] is dispersed in distilled water to about 10<-5>-10<-1>mol/l concn. and this dispersion liq. is subjected to ultrasonic treatment at about 70-80 deg.C to produce a fibrous aggregate of micromolecules. This aggregate capable of stably retaining its shape over a long time can be very easily obtd. from the high purity starting material as compared with a case using biolipid.
The invention discloses a preparation method of fructus kochiae oral liquid, and aims to provide an oral liquid which smoothens the vein and has diuresis effect. The technical scheme adopted by the invention is as follows: the fructus kochiae, gourd flesh, angelica sinensis and cured hay are selected for boiling so as to obtain a decoction. The invention discloses the preparation method of the fructus kochiae oral liquid. The method comprises the following steps of: (1) selecting the fructus kochiae, gourd flesh, angelica sinensis and cured hay to form a formula in the ratio of 5: 3: 1: 1: in sequence; (2) adding water to boil at slow fire; (3) filtering the medicament liquid; (4) packaging the fructus kochiae oral liquid under vacuum; and (5) shading and storing. The technical scheme adopted by the invention is simple and convenient for operation. The fructus kochiae oral liquid is suitable for a patient who cannot urinate smoothly; and the fructus kochiae oral liquid has low side effect.
A compsn. for topical application for treatment of toothache etc. comprises an aq. alcoholic solvent contg. as active materials sage oil, eucalyptus oil and clove oil. A claimed compsn. comprises 0.75 vol.% sage oil, 0.75 vol.% eucalyptus oil and 0.40 vol.% clove oil in 96% ethyl alcohol. USE/ADVANTAGE - The compsn. when applied directly to the site of toothache and other painful conditions of the oral cavity gives rapid relief of pain and redn. of inflammation together with a disinfecting action. The compsn. is made from wholly natural prods. and the topical application avoids the secondary effects such as stomach and liver disorders which may be caused by conventional systemic analgesics.
The intervention includes utilizing Clinical and Patient Decision Support Software (RoadMABTM) that will guide the selection of the first infliximab dose followed by subsequent infliximab dose and dosing interval during the maintenance phase. During induction, three infusions will occur at 0, 2 and 6 weeks, respectively. The RoadMABTM dashboard will utilize PK modeling software to provide an infliximab starting dose recommendation (range of 5-12 mg/kg) based on the patients biochemical profile. As noted, dosing frequency (weeks) during induction will not be altered during this study. Following the first three doses, the clinician will be informed of their patients PK profile within the RoadMABTM program and with a shared document (paper). RoadMABTM will provide additional dosing recommendations after each infusion (based on the latest drug concentration measures and blood biomarkers) with the final dose and interval selected by the treating physician.
In controlled clinical trials, bisoprolol fumarate/hydrochlorothiazide 6.25 mg has been shown to reduce systolic and diastolic blood pressure throughout a 24-hour period when administered once daily. The effects on systolic and diastolic blood pressure reduction of the combination of bisoprolol fumarate and hydrochlorothiazide were additive. Further, treatment effects were consistent across age groups (<60, ≥ 60 years), racial groups (black, nonblack), and gender (male, female).

In two randomized, double-blind, placebo-controlled trials conducted in the U.S., reductions in systolic and diastolic blood pressure and heart rate 24 hours after dosing in patients with mild-to‑moderate hypertension are shown below. In both studies mean systolic/diastolic blood pressure and heart rate at baseline were approximately 151/101 mm Hg and 77 bpm.

     a Observed mean change from baseline minus placebo.

Blood pressure responses were seen within 1 week of treatment but the maximum effect was apparent after 2 to 3 weeks of treatment. Overall, significantly greater blood pressure reductions were observed on bisoprolol fumarate and hydrochlorothiazide tablets than on placebo. Further, blood pressure reductions were significantly greater for each of the bisoprolol fumarate plus hydrochlorothiazide combinations than for either of the components used alone regardless of race, age, or gender. There were no significant differences in response between black and nonblack patients.
Chronic Obstructive Pulmonary Disease (COPD) remains the fourth leading cause of chronic morbidity and mortality at the global level, and it represents a major problem for public health. It is known that expiratory muscles are usually activated at the end of expiration in COPD patients during rest, or weight-bearing breathing to compensate weakness of inspiratory muscle and lung hyperinflation by time, expiratory muscle fatigue and weakness take place and more lung deterioration affecting COPD patient functional capacity occur.

The efficacy of pulmonary rehabilitation on chronic obstructive pulmonary disease (COPD) patients has been demonstrated in many studies. Although pulmonary rehabilitation is a multi-dimensional therapy, respiratory muscle training and strengthening appears to be its most effective component, expiratory muscle training improves functional exercise capacity as assessed by timed walking distance, and decreases dyspnea during daily living activities, resulting in a better health-related quality of life in patients with COPD. Russian current is a medium frequency current, which was developed for improving muscle strength. There is limited literature on the effect of Russian current in improving strength of respiratory muscles. Thus, a need arises which addresses this perspective for new management strategies
Disclosed are animal feed compositions comprising a saponin extracted from a non-woody plant of the genus Hesperaloe. The saponin containing extracts, which generally constitute the water soluble fraction, are useful as additives to basal animal feed to reduce the production of ammonia. In certain embodiments, saponin containing compositions of the present invention may inhibit proteolytic microorganisms, reducing ammonia and improving animal welfare and animal performance. In other embodiments, administration of saponin containing compositions of the present invention to non-human animal inhibits the release of gaseous ammonia through the inhibition urease. The compositions of the present invention may be administered to non-human animals, particularly poultry, to reduce ammonia emissions. In certain embodiment, the animal feed composition comprises a basal animal feed and an extract from a non-woody plant of the genus Hesperaloe, the extract comprising 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin, yuccaloiside, or a mixture thereof.
The invention discloses application of non-sulfated polysaccharide to preparation of a guided bone regeneration drug. According to the invention, polysaccharide is used for preparing the guided bone regeneration drug, cooperates with BMP-2 to promote regeneration of bone cells, and has the advantages of high activity and stability. The molecular weight of polysaccharide is smaller, and absorption and metabolism of an organism are facilitated due to no antigenicity; in addition, polysaccharide does not contain sulfate groups and is simple in structure, so that the drug activity is stable. Polysaccharide is found in the corpora lutea of sea urchins initially, so that risks, such as the risk of transmitting mammal viruses by heparin extracted from pigs and cattle, that viruses contained in a mammal preparation infect human bodies are avoided through the application of polysaccharide. Polysaccharide is stable in structure and high in active function, and side effects caused by application of heparin drugs are avoided. Polysaccharide can substitute for heparin in the application to the preparation of drugs for organ transplantation, bone injuries, osteoporosis and the like.